Procyon Technologies and Klearchos Papas are mentioned in a Nature Biotechnology article published in Feb 2022, see Diabetes cell therapies take evasive action. “Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.”
